ARTL Artelo Biosciences Inc. Quarterly EPS earnings growth

Public company logo of Artelo Biosciences Inc. (ARTL)

Artelo Biosciences (ARTL) relies on strict ESG standards in the development of anti-cancer modulators. The quarterly EPS growth efficiency metric confirms market trends, where the value of 97.30 reflects current dynamics. High scaling potential is ensured through the global replication of patents. A unique biotechnological portfolio for combating cachexia allows Artelo Biosciences (ARTL) to avoid direct pricing wars with other players.

Artelo Biosciences Inc. (ARTL) Year-over-year earnings per one share growth for the last 12 months: for the period 07/04/2022 - 11/16/2026

Analytical breakdowns for Artelo Biosciences

- market value and analyst target forecast:
Fundamental valuation:Artelo Biosciences
Flagship merchandise of artelobio.com

Quarterly EPS growth measures the percentage change in net income per share compared to the same period, allowing investors to filter out market noise and identify actual business efficiency. An analysis of quarterly EPS dynamics confirms the resilience of Artelo Biosciences (ARTL), whose narrow specialization in cannabinoids and patent protection of formulas ensure stable monetization of cancer therapy.

Analysis of competing companies

Indivior Corp (INDV) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share growth for the last 12 months Collegium Pharmaceutical Inc|CRON (thecronosgroup.com) - Quarterly EPS earnings growth|Quarterly EPS earnings growth canopygrowth.com|Quarterly EPS earnings growth HITI|ACB (Aurora Cannabis, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth ACHV (Achieve Life Sciences, Inc)|Skye Bioscience (SKYE) - Earnings per share growth in annualized terms for the last twelve months|Anebulo Pharmaceuticals - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months InterCure|NTRB: Quarterly EPS earnings growth|NSRX - Year-over-year net earnings per share change for the last twelve months|IGC (IGC Pharma Inc) - Quarterly EPS earnings growth|MIRA Pharmaceuticals - Year-over-year net earnings per share trend for the last twelve months|Quarterly EPS earnings growth FLGC|IM Cannabis - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth ADIL (Adial Pharmaceuticals)|Year-over-year earnings per one share growth for the last 12 months ENSC|Titan Pharmaceuticals - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Greenlane Holdings|inmedpharma.com (INM) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months AKAN|Year-over-year earnings per share growth for the last twelve months Enveric Corp|Earnings per share growth in annualized terms for the last twelve months brightgreen.us BGXX|Year-over-year net earnings per share growth for the last 12 months HPCO (Hempacco Co Inc.)